查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1527164

多重特异性抗体的全球市场:药物销售额，药价，临床试验趋势(2029年)

Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029
出版日期: | 出版商: KuicK Research | 英文 1200 Pages | 商品交期: 最快1-2个工作天内

价格

下一代多特异性抗体市场是生物技术和药物开发领域令人兴奋的前沿领域，为创新和成长提供了重大机会。这些工程蛋白可以同时结合两个或更多不同的靶点，正在彻底改变治疗方法，特别是在癌症领域。该领域正迅速从传统的双特异性抗体发展到更复杂的三特异性和四特异性抗体，每种抗体都可以针对多种疾病途径或对针对癌细胞的免疫反应做出反应，在增强癌细胞免疫反应方面具有独特的优势。

目前，双特异性抗体在下一代已获批准的多特异性抗体中占据主导地位，有 13 种产品在全球范围内获得监管批准。这项初步成功为更复杂的多特异性抗体铺平了道路，并凸显了进一步市场扩张的潜力。这些创新疗法的市场在 2023 年达到了一个重要的里程碑，全球销售额超过 80 亿美元。这些令人印象深刻的数字证实了临床实践中，特别是肿瘤学中对多特异性抗体的令人印象深刻的功效和安全性、接受度以及不断增长的需求。

下一代多特异性抗体的主要用途是在癌症治疗中，它们已显示出改善传统单株抗体疗法的能力。例如，用于治疗小细胞肺癌的双特异性 T 细胞接合剂 (BiTE) 可同时与 T 细胞上的 CD3 和肿瘤细胞上的 DLL3 结合，有效杀死癌细胞并使效应细胞紧密结合。这种机制在这种罕见且快速生长的肺癌中显示出了令人印象深刻的结果。其他活动包括用于瀰漫性大 B 细胞淋巴瘤的 epcolitab 和用于多发性骨髓瘤的 tarketamab，这两种药物都利用双特异性技术来增强抗癌活性。

下一代多特异性抗体的市场机会庞大且多方面。目前核准的 13 种双特异性抗体还有扩展的空间。随着更复杂的多特异性抗体的临床试验的进展，新的批准将会激增，每一个都有可能解决未满足的医疗需求或提高现有治疗的疗效。

本报告提供全球多重特异性抗体市场相关调查，提供市场概要，以及药物趋势，临床试验趋势，各地区趋势，及加入此市场的主要企业的竞争情形等资讯。

目录

第1章 下一代多重特异性抗体的简介

第2章 多重特异性抗体的目前临床开发与未来的商业化的展望

  • 目前市场概要
  • 未来的商业化的机会

第3章 企业的多重特异性抗体的专利技术

第4章 多重特异性抗体临床开发与市场趋势，各地区

  • 美国
  • 欧洲联盟
  • 中国
  • 英国
  • 日本
  • 澳洲
  • 韩国
  • 加拿大

第5章 多重特异性抗体临床趋势，各适应症

  • 癌症
  • 血液疾病
  • 微生物感染疾病
  • 自体免疫疾病及发炎性疾病
  • 眼科疾病

第6章 已通过核准多重特异性抗体- 临床概要，价格设定，剂量相关考察

  • 概要
  • 临床概要，价格设定，剂量相关洞察

第7章 已通过核准多重特异性抗体- 销售额预测(2020年～2024年前半期)

第8章 全球多重特异性抗体- 临床试验概要(2024年～2029年)

  • 不同阶段
  • 各国各地区
  • 各企业
  • 各适应症
  • 各优先级
  • 患者市场区隔

第9章 企业，适应症，不同阶段的全球二特异性抗体临床试验

  • 研究
  • 前临床
  • 第一阶段
  • 第一/二阶段
  • 第二阶段
  • 第二/三阶段
  • 第三阶段
  • 预註册

第10章 市售被做的二特异性抗体的各企业，各国，各适应症的临床性洞察

第11章 企业，国家，适应症，不同阶段的全世界的三特异性抗体- 临床试验的洞察

  • 调查
  • 前临床
  • 第一阶段
  • 第一/二阶段

第12章 四特异性抗体的临床试验相关企业，国家，适应症，不同阶段的考察

  • 前临床
  • 第一阶段
  • 第一/二阶段
  • 第二阶段

第13章 竞争情形

Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 Report Highlights:

  • Global & Regional Market Analysis
  • Global Multispecific Antibodies Market Opportunity: > USD 40 Billion
  • Global Multispecific Antibodies Market Sales In 2023: > USD 8 Billion
  • Number Of Approved Multispecific Antibodies: 13
  • Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
  • Approved Antibodies Dosage & Pricing Insight
  • Number Of Multispecific Antibodies: In Clinical Trials: > 900
  • Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication, & Phase

The market for next generation multispecific antibodies represents an exciting frontier in biotechnology and pharmaceutical development, offering significant opportunities for innovation and growth. These engineered proteins, capable of binding to two or more different targets simultaneously, are revolutionizing therapeutic approaches, especially in oncology. The field has rapidly evolved from the traditional bispecific antibodies to more complex trispecific and tetraspecific constructs, each offering unique advantages in targeting multiple disease pathways or enhancing immune responses against cancer cells.

Currently, bispecific antibodies dominate the approved next generation multispecific antibodies landscape, with 13 products having received regulatory green light around the globe. This initial success has paved the way for more complex multispecific antibodies, highlighting the potential for further market expansion. The market for these innovative therapies crossed a significant milestone in 2023, surpassing US$ 8 billion in global sales. This impressive figure underscores the growing acceptance and demand for multispecific antibodies in clinical practice, particularly in oncology, where they have shown impressive efficacy and safety profiles.

The primary application of next generation multispecific antibodies has been in cancer treatment where they have demonstrated the ability to improve upon traditional monoclonal antibody therapies. For example, bispecific T-cell engagers (BiTE), like Tarlatamab, used in the treatment of small cell lung cancer, simultaneously bind to CD3 on T cells and DLL3 on tumor cells, effectively bringing cancer cells and effector cells in close proximity. This mechanism has shown impressive results in this rare, fast-growing lung cancer. Other examples include Epcoritamab for diffuse large B-cell lymphoma and Talquetamab for multiple myeloma, both leveraging bispecific technology to enhance anti-cancer activity.

The development of trispecific and tetraspecific antibodies represents the next wave of innovation in the field. These more complex molecules offer the potential to engage multiple proteins or immune cell types simultaneously, potentially leading to more precise and potent therapeutic effects. For example, researchers from the Osaka Metropolitan University and Tokyo University of Agriculture and Technology jointly developed a series of trispecific antibodies to engage T cells and NK cells simultaneously against tumors overexpressing the EGFR receptor, potentially offering a more robust anti-tumor response than bispecific antibodies.

The market opportunity for next-generation multispecific antibodies is substantial and multifaceted. There is room for expansion beyond the current 13 approved bispecific antibodies. As more complex multispecific antibodies progress through clinical trials, we can expect a surge in new approvals, each potentially addressing unmet medical needs or offering improved efficacy over existing therapies.

Moreover, the versatility of multispecific antibodies opens doors to applications beyond oncology. While cancer remains the primary focus, research is underway to apply this technology to autoimmune diseases, infectious diseases and neurological disorders. The diversification of therapeutic areas represents a vast untapped market potential. At present, Hemlibra stands at the forefront of multispecific antibodies developed for non-cancer indications, cementing its place as the highest-selling bispecific antibody in the market for several years consecutively.

The financial trajectory of the multispecific antibody market is highly promising. Having crossed the US$ 8 billion market in 2023, our analysis projects continues robust growth and the market is expected to surpass USD 40 Billion by 2029. Factors driving this growth include the increasing incidence of cancer worldwide, growing acceptance of immunotherapy approaches, and the potential for these therapies to commands premium pricing due to their complex engineering and enhanced efficacy.

In conclusion, the next generation multispecific antibody market presents a compelling opportunity for growth and innovation in the biopharmaceutical industry. With its strong foundation in bispecific antidotes and the emerging potential of tri- and tetraspecific antibodies, this field is poised for significant expansion beyond its currently US$ 8 billion market size. As research progresses and more products receive approved, multispecific antibodies are set to play an increasingly important role in the treatment of cancer and potentially other diseases, offering substantial rewards for companies at the forefront of this technological revolution.

Table of Contents

1. Introduction to Next Generation Multispecific Antibodies

2. Multispecific Antibody Current Clinical Development & Future Commercialization Outlook

  • 2.1 Current Market Overview
  • 2.2 Future Commercialization Opportunity

3. Multispecific Antibody Proprietary Technologies by Company

4. Multispecific Antibody Clinical Development & Market Trends by Region

  • 4.1 US
  • 4.2 EU
  • 4.3 China
  • 4.4 UK
  • 4.5 Japan
  • 4.6 Australia
  • 4.7 South Korea
  • 4.8 Canada

5. Multispecific Antibody Clinical Trends by Indication

  • 5.1 Cancer
  • 5.2 Hematological Disorders
  • 5.3 Microbial Infections
  • 5.4 Autoimmune & Inflammatory Disorders
  • 5.5 Ocular Diseases

6. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight

  • 6.1 Overview
  • 6.2 Clinical Overview, Pricing & Dosage Insight

7. Approved Multispecific Antibodies - Sales Insight ( 2020 - H1'2024)

8. Global Multispecific Antibodies Clinical Trials Overview (2024 - 2029)

  • 8.1 By Phase
  • 8.2 By Country/Region
  • 8.3 By Company
  • 8.4 By Indication
  • 8.5 By Priority Status
  • 8.6 Patient Segment

9. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Phase-I
  • 9.4 Phase-I/II
  • 9.5 Phase-II
  • 9.6 Phase-II/III
  • 9.7 Phase-III
  • 9.8 Preregistration

10. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

11. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 11.1 Research
  • 11.2 Preclinical
  • 11.3 Phase I
  • 11.4 Phase I/II

12. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 12.1 Preclinical
  • 12.2 Phase I
  • 12.3 Phase I/II
  • 12.4 Phase II

13. Competitive Landscape

This Chapter Gives Insight On 55 Companies Involved in Clinical Trials Of Multispecific Antibodies

List of Figures

  • Figure 2-1: Global -Multispecific Antibodies Sales (US$ Million), 2020-2024
  • Figure 2-2: Global - Market Sales by Multispecific Antibodies (US$ Million), 2024
  • Figure 2-3: Global -Market Sales by Multispecific Antibodies (%), 2024
  • Figure 2-4: Global - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
  • Figure 2-5: Global - Quarterly Sales By Multispecific Antibodies (%), 2024
  • Figure 2-6: US - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
  • Figure 2-7: ROW - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
  • Figure 2 8: Global - Multispecific Antibodies Market Opportunity Assessment (US$ Billion), 2024 - 2029
  • Figure 3-1: Grabody I Platform - Mechanism of Action
  • Figure 3-2: Grabody I Platform - Mechanism of Action
  • Figure 3-3: Abz2 Bispecific Platform
  • Figure 3-4: Abz2 Bispecifics - Benefits
  • Figure 3-5: Neo-X-Prime Bispecific Mechanism
  • Figure 3-6: BiTE - Structure
  • Figure 3-7: BiTE Molecule
  • Figure 3-8: ADAPTIR Bispecific Structure
  • Figure 3-9: ADAPTIR-FLEX
  • Figure 3-10: BioAtla CABs - Features
  • Figure 3-11: BioAtla CABs - Benefits
  • Figure 3-12: FIT-Ig - Proprietary Bispecific Platform
  • Figure 3-13: 3-Step DuoBody Production Process
  • Figure 3-14: DuoHexaBody Molecules - Schematic
  • Figure 3-15: BEAT Platform - Multispecific Antibodies
  • Figure 3-16: IMBiologic Bispecific Antibodies - Strategy
  • Figure 3-17: IMBiologic Bispecific Antibodies - Mechanism of Action
  • Figure 3-18: ANKET-R Platform - Innate Pharma
  • Figure 3-19: B-Body Bispecific Antibody - Structre
  • Figure 3-20: iTAb - Patented Structure
  • Figure 3-21: iTAb - Mechanism of Action
  • Figure 3-22: xLinkBsAb - Structure
  • Figure 3-23: Multiclonics - Distinctive Characteristics
  • Figure 3-24: Biclonics - Format
  • Figure 3-25: Merus - Triclonics Platform
  • Figure 3-26: STEALTH - ModeX Therapeutics
  • Figure 3-27: MSTAR - ModeX Therapeutics
  • Figure 3-28: MSTAR - Features
  • Figure 3-29: DARPin Platform - Molecular Partners
  • Figure 3-30: Novel HBICE
  • Figure 3-31: HBICE - Mechanism of Action 1
  • Figure 3-32: HBICE - Mechanism of Action 2
  • Figure 3-33: Numab Therapeutics - Technology
  • Figure 3-34: Phanes Therapeutics - PACbody Platform
  • Figure 3-35: Phanes Therapeutics - SPECpair Platform
  • Figure 3-36: Phanes Therapeutics - ATACCbody
  • Figure 3-37: Purple Biotech - Tribody Antibody Platform
  • Figure 3-38: PrecisionGATE Bispecific Antibody - Structure
  • Figure 3-39: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
  • Figure 3-40: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
  • Figure 3-41: Synimmune - Proprietary Bispecific Antibody Format
  • Figure 3-42: ALiCE - Characteristics
  • Figure 3-43: ALiCE - Schematic Diagram & Mechanism of Action
  • Figure 3-44: BiClone format
  • Figure 3-45: Zyngenia Technology Approach
  • Figure 4-1: US - Approved Bispecific Antibodies
  • Figure 4-2: Chugai Files New Drug Application in Japan for Mosunetuzumab, anti-CD20xCD3 bispecific antibody
  • Figure 4-3: Chugai Pharmaceutical - Multispecific Antibody Clinical Pipeline
  • Figure 4-4: SAIL66 Phase I Study (NCT05735366) - Initiation & Completion Year
  • Figure 4-5: Japan Next Generation Multispecific Antibody Market - Insight
  • Figure 4-6: Hoffmann La Roche AG Patent (JP2018502835A) - Grant & Expiration Year
  • Figure 4-7: DR-0201 Phase I Study (NCT06392477) - Initiation & Completion Year
  • Figure 4-8: Australia - Universities & Research Centers Conducting Next Generation Multispecific Antibody Clinical Trials
  • Figure 4-9: ABL Bio - Bispecific Antibody Pipeline
  • Figure 4-10: Multispecific Antibody Combinations
  • Figure 4-11: CTX-009 (ABL001) Phase I/II Study (NCT04492033) - Initiation & Completion Year
  • Figure 4-12: Elranatamab Phase II Study (NCT06421675) - Initiation & Completion Year
  • Figure 4-13: Canada Next Generation Multispecific Antibodies - Key Players
  • Figure 5-1: Odronextamab (ELM-1) Phase I (NCT02290951) Study - Initiation & Completion Year
  • Figure 5-2: Odronextamab (ELM-1) Phase II (NCT03888105) Study - Initiation & Completion Year
  • Figure 5-3: Linvoseltamab (LINKER-MM1) Phase I/II (NCT03761108) Study - Initiation & Completion Year
  • Figure 5-4: PIT565 Phase I (NCT05397496) Study - Initiation & Completion Year
  • Figure 5-5: JNJ-79635322 Phase I (NCT05652335) Study - Initiation & Completion Year
  • Figure 5-6: GNC-038 Phase I/II (NCT05192486) Study - Initiation & Completion Year
  • Figure 5-7: GNC-038 Phase I/II (NCT05485753) Study - Initiation & Completion Year
  • Figure 5-8: IPH6501 Phase I/II (NCT06088654) Study - Initiation & Completion Year
  • Figure 5-9: NM32-2668 Phase I (NCT06299163) Study - Initiation & Completion Year
  • Figure 5-10: GB263T Phase I/II (NCT05332574) Study - Initiation & Completion Year
  • Figure 5-11: GNC-039 Phase I (NCT04794972) Study - Initiation & Completion Year
  • Figure 5-12: Emicizumab Phase II (NCT05345197) Study - Initiation & Completion Year
  • Figure 5-13: Emicizumab Phase II/III (NCT06155955) Study - Initiation & Completion Year
  • Figure 5-14: Emicizumab (BCDI-XII) Phase I (NCT05500807) Study - Initiation & Completion Year
  • Figure 5-15: HMB-001 Phase I/II (NCT06211634) Study - Initiation & Completion Year
  • Figure 5-16: YBSW015 Early Phase I (NCT05369754) Study - Initiation & Completion Year
  • Figure 5-17: GR1801 Phase III (NCT05846568) Study - Initiation & Completion Year
  • Figure 5-18: Imvotamab (IGM-2323-101) Phase I (NCT06041568) Study - Initiation & Completion Year
  • Figure 5-19: Imvotamab (IGM-2323-102) Phase I (NCT06087406) Study - Initiation & Completion Year
  • Figure 5-20: PRV-3279 (PREVAIL-2) Phase II (NCT05087628) Study - Initiation & Completion Year
  • Figure 5-21: DONQ52 (DQB101US) Phase I (NCT05425446) Study - Initiation & Completion Year
  • Figure 5-22: Mosunetuzumab (GA43191) Phase I (NCT05155345) Study - Initiation & Completion Year
  • Figure 5-23: Faricimab (MAGIC) Phase II (NCT05681884) Study - Initiation & Completion Year
  • Figure 5-24: Restoret (EYE103) - Tetravalent, Tri-Specific Antibody Binding Sites
  • Figure 5-25: EYE103 (AMARONE) Phase I/II Study (NCT05919693) - Initiation & Completion Year
  • Figure 6-1: Blincyto - Approval Year by Region
  • Figure 6-2: Blincyto - Patent Filing & Expiration Year
  • Figure 6-3: Blincyto - Treatment Regimen Cycles (Weeks)
  • Figure 6-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
  • Figure 6-5: Blincyto - Cost of Single Cycle & Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
  • Figure 6-6: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
  • Figure 6-7: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
  • Figure 6-8: Blincyto - Cost of Single Cycle & Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
  • Figure 6-9: Hemlibra - Approval Years by Region
  • Figure 6-10: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), July'2024
  • Figure 6-11: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), July'2024
  • Figure 6-12: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
  • Figure 6-13: Rybrevant - Price per Unit & Supply of Intravenous Solution (US$), July'2024
  • Figure 6-14: Rybrevant - Recommended Dose per Cycle by Body Weight (mg)
  • Figure 6-15: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
  • Figure 6-16: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
  • Figure 6-17: Vabysmo - First Approval Year by Region
  • Figure 6-18: Vabysmo - Price per Unit & Supply of Intravitreal Solution (US$), July'2024
  • Figure 6-19: Lunsumio - Approval Years by Region
  • Figure 6-20: US - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), July'2024
  • Figure 6-21: EU - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), July'2024
  • Figure 6-22: Tecvayli - Approval Years by Region
  • Figure 6-23: Tecvayli - Patent Acceptance & Expiration Years
  • Figure 6-24: US - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), July'2024
  • Figure 6-25: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), July'2024
  • Figure 6-26: Columvi - Approval Year by Region
  • Figure 6-27: US - Price per Unit & Supply of Columvi Intravenous Solution (US$), July'2024
  • Figure 6-28: EU - Price per Unit & Supply of Columvi Intravenous Solution (US$), July'2024
  • Figure 6-29: Epkinly - Approval Year by Region
  • Figure 6-30: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), July'2024
  • Figure 6-31: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), July'2024
  • Figure 6-32: Talvey - Approval Year by Region
  • Figure 6-33: Talquetamab - FDA & EMA Designation Year
  • Figure 6-34: Talvey - Patent Acceptance & Expiration Year
  • Figure 6-35: US - Price per Unit & Supply of Talvey Intravenous Solution (US$), July'2024
  • Figure 6-36: EU - Price per Unit & Supply of Talvey Intravenous Solution (US$), February'2024
  • Figure 6-37: Elrexfio - Approval Years by Region
  • Figure 6-38: Elranatamab - FDA & EMA Designation Year
  • Figure 6-39: US - Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), July'2024
  • Figure 7-1: Global - Annual Blincyto Sales (US$ Million), 2020-2024
  • Figure 7-2: Global - Quarterly Blincyto Sales (US$ Million), 2024
  • Figure 7-3: Blincyto - US v/s ROW Sales (US$ Million), H1'2024
  • Figure 7-4: Global - Blincyto Sales by Region (%), Q1'2024
  • Figure 7-5: US - Quarterly Blincyto Sales (US$ Million), 2024
  • Figure 7-6: ROW - Quarterly Blincyto Sales (US$ Million), H1'2024
  • Figure 7-7: Global - Quarterly Blincyto Sales (US$ Million), 2023
  • Figure 7-8: US - Quarterly Blincyto Sales (US$ Million), 2023
  • Figure 7-9: ROW - Quarterly Blincyto Sales (US$ Million), 2023
  • Figure 7-10: US - Annual Blincyto Sales (US$ Million), 2020-2024
  • Figure 7-11: ROW - Annual Blincyto Sales (US$ Million), 2019-2023
  • Figure 7-12: Global - Annual Hemlibra Sales (US$ Million), 2020-2024
  • Figure 7-13: Regional - US v/s ROW Sales (US$ Million), H1'2024
  • Figure 7-14: Global - Hemlibra Sales by Region (US$ Million), H1'2024
  • Figure 7-15: Global - Hemlibra Sales by Region (%), H1'2024
  • Figure 7-16: US - Annual Hemlibra Sales (US$ Million), 2020-2024
  • Figure 7-17: Europe - Annual Hemlibra Sales (US$ Million), 2020-2024
  • Figure 7-18: Japan - Annual Hemlibra Sales (US$ Million), 2020-2024
  • Figure 7-19: ROW - Hemlibra Sales (US$ Million), 2020-2024
  • Figure 7-20: Global - Hemlibra Annual Sales by Region (US$ Million), 2023
  • Figure 7-21: Global - Hemlibra Sales by Region (%), 2023
  • Figure 7-22: Global - Quarterly Hemlibra Sales (US$ Million), 2023
  • Figure 7-23: US - Quarterly Hemlibra Sales (US$ Million), 2023
  • Figure 7-24: Europe - Quarterly Hemlibra Sales (US$ Million), 2023
  • Figure 7-25: Japan - Quarterly Hemlibra Sales (US$ Million), 2023
  • Figure 7-26: ROW - Quarterly Hemlibra Sales (US$ Million), 2023
  • Figure 7-27: Global - Annual Vabysmo Sales (US$ Million), 2022-2024
  • Figure 7-28: Global - Vabysmo US v/s ROW Sales (US$ Million), H1'2024
  • Figure 7-29: Global - Vabysmo Sales by Region (US$ Million), H1'2024
  • Figure 7-30: Global - Vabysmo Annual Sales by Region (%), H1'2024
  • Figure 7-31: Global - Vabysmo US v/s ROW Sales (US$ Million), 2023
  • Figure 7-32: Global - Vabysmo Annual Sales by Region (US$ Million), 2023
  • Figure 7-33: Global - Vabysmo Annual Sales by Region (%), 2023
  • Figure 7-34: US - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 7-35: Europe - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 7-36: Japan - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 7-37: ROW - Vabysmo Sales (US$ Million), 2022-2024
  • Figure 7-38: Global - Quarterly Vabysmo Sales (US$ Million), 2023
  • Figure 7-39: US - Quarterly Vabysmo Sales (US$ Million), 2023
  • Figure 7-40: Europe - Quarterly Vabysmo Sales (US$ Million), 2023
  • Figure 7-41: Japan - Quarterly Vabysmo Sales (US$ Million), 2023
  • Figure 7-42: ROW - Quarterly Vabysmo Sales (US$ Million), 2023
  • Figure 7-43: Global - Annual Lunsumio Sales (US$ Million), 2022-2024
  • Figure 7-44: US - Annual Lunsumio Sales (US$ Million), 2022-2024
  • Figure 7-45: Europe - Annual Lunsumio Sales (US$ Million), 2022-2024
  • Figure 7-46: Global - Lunsumio Sales by Region (US$ Million), H1'2024
  • Figure 7-47: Global - Lunsumio Sales by Region (%), H1'2024
  • Figure 7-48: Global - Lunsumio Annual Sales by Region (US$ Million), 2023
  • Figure 7-49: Global - Lunsumio Annual Sales by Region (%), 2023
  • Figure 7-50:- Global -Lunsumio Sales (US$ Million), Q1 - Q4'2023
  • Figure 7-51: US - Quarterly Lunsumio Sales (US$ Million), 2023
  • Figure 7-52: Europe - Quarterly Lunsumio Sales (US$ Million), 2023
  • Figure 7-53: Global - Annual Tecvayli Sales (US$ Million), 2024
  • Figure 7-54: Regional - US v/s ROW Sales (US$ Million), H1'2024
  • Figure 7-55: Global - Tecvayli Sales by Region (%), H1'2024
  • Figure 7-56: Global - Quarterly Tecvayli Sales (US$ Million), 2024
  • Figure 7-57: US - Quarterly Tecvayli Sales (US$ Million), 2024
  • Figure 7-58: ROW - Quarterly Tecvayli Sales (US$ Million), 2024
  • Figure 7-59: Global - Quarterly Tecvayli Sales (US$ Million), 2023
  • Figure 7-60: US - Quarterly Tecvayli Sales (US$ Million), 2023
  • Figure 7-61: ROW - Quarterly Tecvayli Sales (US$ Million), 2023
  • Figure 7-62: Global - Annual Columvi Sales (US$ Million), 2022-2024
  • Figure 7-63: Global - Columvi Sales by Region (US$ Million), H1'2024
  • Figure 7-64: Global - Columvi Sales by Region (%), H1'2024
  • Figure 7-65: Global - Columvi Sales by Region (US$ Million), 2023
  • Figure 7-66: Global - Columvi Sales by Region (%), 2023
  • Figure 7-67: Global - Quarterly Columvi Sales (US$ Million), 2023
  • Figure 7-68: US - Quarterly Columvi Sales (US$ Million), 2023
  • Figure 7-69: Europe - Quarterly Columvi Sales (US$ Million), 2023
  • Figure 7-70: Global - Annual Epkinly Sales (US$ Million), 2023-2024
  • Figure 7-71: Global - Quarterly Epkinly Sales (US$ Million), 2024
  • Figure 7-72: Global - Quarterly Epkinly Sales (US$ Million), 2023
  • Figure 7-73: Annual - Cadonilimab Sales (US$ Million), H2'2022 & H1'2023
  • Figure 8-1: Global - Multispecific Antibodies Clinical Trials by Phase (Numbers), 2024 till 2029
  • Figure 8-2: Global - Bispecific Antibodies Clinical Trials by Phase (Numbers), 2024 till 2029
  • Figure 8-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024 till 2029
  • Figure 8-4: Global - Trispecific Antibodies Clinical Trials by Phase, 2024 till 2029
  • Figure 8-5: Global - Bispecific Antibodies in Clinical Trials by Country (Numbers), 2024 till 2029
  • Figure 8-6: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024 till 2029
  • Figure 8-7: Global - Trispecific Antibodies Clinical Trials by Country, 2024 till 2029
  • Figure 8-8: Global - Bispecific Antibodies in Clinical Trials by Company (Numbers), 2024 till 2029
  • Figure 8-9: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024 till 2029
  • Figure 8-10: Global - Trispecific Antibodies Clinical Trials by Company, 2024 till 2029
  • Figure 8-11: Global - Bispecific Antibodies in Clinical Trials by Indication (Numbers), 2023 till 2029
  • Figure 8-12: Global - Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024 till 2029
  • Figure 8-13: Global - Trispecific Antibodies Clinical Trials by Indication, 2024 till 2029
  • Figure 8-14: Global - Bispecific Antibodies in Clinical Trials by Orphan Status (Numbers), 2024 till 2029
  • Figure 8-15: Global - Bispecific Antibodies in Clinical Trials by Patient Segment (Numbers), 2024 till 2029
  • Figure 8-16: Global - Trispecific Antibodies Clinical Trials by Patient Segment, 2024 till 2029
  • List of Tables
  • Table 2-1: Estimated Total Cancer Cases, 2022 & 2040
  • Table 2-2: Next Generation Multispecific Antibody Market - Recent Collaborations
  • Table 2-3: Next Generation Multispecific Antibody Market - Recent Acquisitions
  • Table 2-4: Next Generation Multispecific Antibody Market - Recent Regulatory
  • Designations
  • Table 4-1: US - Multispecific Antibodies in Clinical Trials
  • Table 4-2: Europe - Multispecific Antibodies in Clinical Trials
  • Table 4-3: China - Multispecific Antibodies in Clinical Trials
  • Table 4-4: UK - Multispecific Antibodies in Clinical Trials
  • Table 4-5: Japan - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
  • Table 4-6: Australia - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
  • Table 4-7: South Korea - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
  • Table 4-8: Canada - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
  • Table 5-1: Hematological Cancers - Approved Multispecific Antibodies
  • Table 5-2: Hematological Malignancies - Estimated Total Cancer Cases, 2022 & 2040
  • Table 5-3: Solid Cancers - Approved Multispecific Antibodies
  • Table 5-4: Solid Cancers - Estimated Total Cancer Cases, 2022 & 2040
  • Table 5-5: Vabysmo - Approval Year by Indication
  • Table 6-1: Approved Multispecific Antibodies
  • Table 6-2: Blincyto - Active Patents
  • Table 6-3: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
  • Table 6-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
  • Table 6-5: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
  • Table 6-6: Rybrevant - Premedication
  • Table 6-7: Rybrevant - Dose Reductions for Adverse Reactions
  • Table 6-8: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
  • Table 6-9: Lunsumio - Recommended Treatment Cycles
  • Table 6-10: Lunsumio - Recommended Premedications
  • Table 6-11: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
  • Table 6-12: Tecvayli - Dosing Schedule
  • Table 6-13: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
  • Table 6-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
  • Table 6-15: Columvi - Premedications to be Administered
  • Table 6-16: Columvi - Recommendations for Management of Cytokine Release Syndrome
  • Table 6-17: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
  • Table 6-18: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 6-19: Epkinly - Dosage Schedule
  • Table 6-20: Epkinly - Recommendations for Management of Cytokine Release Syndrome
  • Table 6-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 6-22: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 6-23: Talvey - Weekly Dosing Schedule
  • Table 6-24: Talvey - Biweekly Dosing Schedule
  • Table 6-25: Talvey - Recommendations for Management of CRS
  • Table 6-26: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 6-27: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
  • Table 6-28: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 6-29: Elrexfio - Dosing Schedule
  • Table 6-30: Elrexfio - Recommendations for Management of CRS
  • Table 6-31: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 6-32: Imdelltra - Recommended Concomitant Medications for Administration for Cycle 1
  • Table 6-33: Imdelltra - Recommended Dosage and Schedule of
  • Table 6-34: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
  • Table 6-35: Imdelltra - Guidelines for Grading and Dosage Modification and Management of Cytokine Release Syndrome
  • Table 6-36: Imdelltra - Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome